who s developing what in global biopharmaceuticals...september 2008 ©espicom business intelligence...

World Leaders in Health Industry Analysis

Who’s Developing What in global biopharmaceuticals?

©Espicom Business Intelligence iiiSeptember 2008

Who’s Developing What in Global Biopharmaceuticals? Table of Contents

ContentsAffymAx........................................................................................................................................................ 1

Key Personnel ............................................................................................................................................................................ 1Company Overview .................................................................................................................................................................. 1Milestones .................................................................................................................................................................................. 2R&D Pipeline .............................................................................................................................................................................. 3

Affymax R&D Pipeline, August 2008 .....................................................................................................................................................................................................3Haematology..........................................................................................................................................................................3

Hematide .............................................................................................................................................................................................3Other.Indications....................................................................................................................................................................4

Innotide ................................................................................................................................................................................................4Adeptide ..............................................................................................................................................................................................5Angiotide .............................................................................................................................................................................................5

Technology ................................................................................................................................................................................ 5Agreements ............................................................................................................................................................................... 6

Takeda.....................................................................................................................................................................................6Entremed.................................................................................................................................................................................7Nektar......................................................................................................................................................................................7

Key Financial Data .................................................................................................................................................................... 8Appraisal & Evaluation ............................................................................................................................................................. 8

Platform,.Pipeline,.Products.................................................................................................................................................8Corporate.Environment.........................................................................................................................................................8

AmbIT.bIOsCIENCEs...................................................................................................................................... 9Key Personnel ............................................................................................................................................................................ 9Company Overview .................................................................................................................................................................. 9Milestones ................................................................................................................................................................................ 10R&D Pipeline ............................................................................................................................................................................ 10

Ambit Biosciences R&D Pipeline, August 2008 ....................................................................................................................................................................................10Oncology...............................................................................................................................................................................10

AC220 ..................................................................................................................................................................................................10AC480 .................................................................................................................................................................................................11AURORA Kinase Inhibitors ..............................................................................................................................................................11BRAF Kinase Inhibitors ....................................................................................................................................................................11JAK2 ....................................................................................................................................................................................................11ABL (T3 151) .......................................................................................................................................................................................11

Technologies............................................................................................................................................................................ 11Kinase.Profiling.Platform....................................................................................................................................................11

Agreements ............................................................................................................................................................................. 12Cephalon...............................................................................................................................................................................12bristol-myers.squibb...........................................................................................................................................................12medarex................................................................................................................................................................................12AstraZeneca..........................................................................................................................................................................12GlaxosmithKline...................................................................................................................................................................13Roche.....................................................................................................................................................................................13Pfizer......................................................................................................................................................................................13

Key Financial Data .................................................................................................................................................................. 13Appraisal & Evaluation ........................................................................................................................................................... 13

Platform,.Pipeline,.Products...............................................................................................................................................13Corporate.Environment.......................................................................................................................................................13

AmbRx.......................................................................................................................................................... 15

©Espicom Business Intelligence September 2008iv

Who’s Developing What in Global Biopharmaceuticals?

Key Personnel .......................................................................................................................................................................... 15Company Overview ................................................................................................................................................................ 15Milestones ................................................................................................................................................................................ 16R&D Pipeline ............................................................................................................................................................................ 16

Human.Growth.Hormone....................................................................................................................................................16ARX201 ...............................................................................................................................................................................................16

Technologies............................................................................................................................................................................ 16ReCODE.Technology.............................................................................................................................................................16

Patents ...................................................................................................................................................................................... 17Agreements ............................................................................................................................................................................. 17

merck.serono........................................................................................................................................................................17Eli.Lilly....................................................................................................................................................................................17Roche.....................................................................................................................................................................................18merck.&.Co............................................................................................................................................................................18



AmyLIN.PHARmACEuTICALs...................................................................................................................... 19Key Personnel .......................................................................................................................................................................... 19Company Overview ................................................................................................................................................................ 19Milestones ................................................................................................................................................................................ 20Marketed Products .................................................................................................................................................................22

metabolism.......................................................................................................................................................................... 22BYETTA (exenatide, AC2993 (synthetic exendin-4)) injection .................................................................................................22SYMLIN (pramlintide acetate) injection .......................................................................................................................................22

R&D Pipeline ............................................................................................................................................................................23Amylin Pharmaceuticals R&D Pipeline, August 2008 ..........................................................................................................................................................................23

metabolism.......................................................................................................................................................................... 23Diabetes .............................................................................................................................................................................................23Obesity ...............................................................................................................................................................................................25

Discontinued Products .......................................................................................................................................................... 27Cardiology.............................................................................................................................................................................27

AC3056 ...............................................................................................................................................................................................27AC2592 ...............................................................................................................................................................................................27

Agreements .............................................................................................................................................................................28Eli.Lilly................................................................................................................................................................................... 28Alkermes............................................................................................................................................................................... 29Nastech................................................................................................................................................................................. 29PsychoGenics....................................................................................................................................................................... 29Kelaroo................................................................................................................................................................................. 29bioseek................................................................................................................................................................................. 30xenome................................................................................................................................................................................ 30Johnson.&.Johnson............................................................................................................................................................. 30Aventis...................................................................................................................................................................................31



ARANA.THERAPEuTICs................................................................................................................................ 33Key Personnel .......................................................................................................................................................................... 33

Table of Contents

©Espicom Business Intelligence vSeptember 2008


Company Overview ................................................................................................................................................................ 33Milestones ................................................................................................................................................................................34R&D Pipeline ............................................................................................................................................................................34

Arana Therapeutics R&D Pipeline, August 2008 .................................................................................................................................................................................34Autoimmune.and.Inflammatory.Diseases.........................................................................................................................35

ART621 ................................................................................................................................................................................................35PMX53 ................................................................................................................................................................................................35

Oncology...............................................................................................................................................................................35ART104 ...............................................................................................................................................................................................35ART010................................................................................................................................................................................................36ART150 ...............................................................................................................................................................................................36ART140 ...............................................................................................................................................................................................36ART101................................................................................................................................................................................................36ART160 ...............................................................................................................................................................................................36

Technologies............................................................................................................................................................................ 37Protein.Engineering.Platforms...........................................................................................................................................37

Patents ...................................................................................................................................................................................... 37Patent Families – Revenue Generating ...............................................................................................................................................................................................38Patent Families – Product Development .............................................................................................................................................................................................38

Agreements .............................................................................................................................................................................38Vegenics............................................................................................................................................................................... 38AVEO.Pharmaceuticals........................................................................................................................................................ 38CsL.Limited.......................................................................................................................................................................... 39GlaxosmithKline.................................................................................................................................................................. 39Centocor............................................................................................................................................................................... 39Abbott.................................................................................................................................................................................. 39EvoGenix.Pty........................................................................................................................................................................ 39Kyowa.Hakko....................................................................................................................................................................... 40greenovation.biotech......................................................................................................................................................... 40


Platform,.Pipeline,.Products...............................................................................................................................................41Corporate.Environment...................................................................................................................................................... 42

ARCA.bIOPHARmA....................................................................................................................................... 43Key Personnel .......................................................................................................................................................................... 43Company Overview ................................................................................................................................................................ 43Milestones ................................................................................................................................................................................44R&D Pipeline ............................................................................................................................................................................44

Cardiology............................................................................................................................................................................ 44Bucindolol ..........................................................................................................................................................................................44

Agreements ............................................................................................................................................................................. 45Laboratory.Corporation.of.America.Holdings.................................................................................................................. 45

Key Financial Data .................................................................................................................................................................. 45Appraisal & Evaluation ...........................................................................................................................................................46

Platform,.Pipeline,.Products.............................................................................................................................................. 46Corporate.Environment...................................................................................................................................................... 46

ARIus.REsEARCH......................................................................................................................................... 47Key Personnel .......................................................................................................................................................................... 47Company Overview ................................................................................................................................................................ 47Milestones ................................................................................................................................................................................48R&D Pipeline ............................................................................................................................................................................48

Table of Contents

©Espicom Business Intelligence September 2008vi


ARIUS Research R&D Pipeline, August 2008 ........................................................................................................................................................................................48Oncology.............................................................................................................................................................................. 49

CD44 Cancer Stem Cell Program/ARH460-16-2 ..........................................................................................................................49Trop-2 Signal Transduction Program/AR47A6.4.2. ....................................................................................................................50CD59 Complement Inhibitor Program/AR36A36.11.1 ...............................................................................................................50CD9 Cancer Stem Cell Program/AR40A746.2.3...........................................................................................................................51AR7BD-33-11A ..................................................................................................................................................................................51Others .................................................................................................................................................................................................51

Technologies............................................................................................................................................................................ 51Patents ...................................................................................................................................................................................... 52Agreements ............................................................................................................................................................................. 52

Centro.de.Immunologia.molecular.(CImAb)......................................................................................................................52xerion.Pharmaceuticals.AG.................................................................................................................................................52PDL.bioPharma.....................................................................................................................................................................53medarex.................................................................................................................................................................................53Oxford.biomedica.................................................................................................................................................................53Genentech.............................................................................................................................................................................53Takeda...................................................................................................................................................................................53

Key Financial Data ..................................................................................................................................................................54Appraisal & Evaluation ...........................................................................................................................................................54


ARyx.THERAPEuTICs................................................................................................................................... 55Key Personnel .......................................................................................................................................................................... 55Company Overview ................................................................................................................................................................ 55Milestones ................................................................................................................................................................................56R&D Pipeline ............................................................................................................................................................................56

ARYx Therapeutics R&D Pipeline, August 2008 ...................................................................................................................................................................................56Gastrointestinal....................................................................................................................................................................57

ATI-7505 .............................................................................................................................................................................................57ATI-24,000 ..........................................................................................................................................................................................57

Cardiology............................................................................................................................................................................ 58ATI-5923 .............................................................................................................................................................................................58ATI-2042 .............................................................................................................................................................................................58

Antipsychotic....................................................................................................................................................................... 58ATI-9242 .............................................................................................................................................................................................58

metabolism.......................................................................................................................................................................... 59ATI-20,000 ..........................................................................................................................................................................................59

Technologies............................................................................................................................................................................ 59Drug.Design.Technology.................................................................................................................................................... 59

Design and Synthesis of Ideal Metabolites .................................................................................................................................59RetroMetabolic Engineering ..........................................................................................................................................................59Evaluation of Metabolism ..............................................................................................................................................................59

Patents ......................................................................................................................................................................................60Agreements .............................................................................................................................................................................60

Procter.&.Gamble................................................................................................................................................................ 60Key Financial Data .................................................................................................................................................................. 61Appraisal & Evaluation ........................................................................................................................................................... 61

Platform,.Pipeline,.Products...............................................................................................................................................61Corporate.Environment...................................................................................................................................................... 62

AsTEx.THERAPEuTICs................................................................................................................................. 63

Table of Contents

©Espicom Business Intelligence viiSeptember 2008


Key Personnel .......................................................................................................................................................................... 63Company Overview ................................................................................................................................................................ 63Milestones ................................................................................................................................................................................64R&D Pipeline ............................................................................................................................................................................ 65

Astex Therapeutics R&D Pipeline, August 2008 ...................................................................................................................................................................................65Oncology.............................................................................................................................................................................. 65

AT7519 ................................................................................................................................................................................................65AT9283 ................................................................................................................................................................................................66AT9311 ................................................................................................................................................................................................66AT13387 ..............................................................................................................................................................................................66AT13148 .............................................................................................................................................................................................67

Technologies............................................................................................................................................................................ 67Drug.Discovery.Platform.....................................................................................................................................................67

PYRAMID ............................................................................................................................................................................................67Patents ...................................................................................................................................................................................... 67Agreements .............................................................................................................................................................................68

Technology........................................................................................................................................................................... 68Cambridge Crystallographic Data Centre ...................................................................................................................................68Daresbury Analytical Research and Technology Service .........................................................................................................68Global Phasing .................................................................................................................................................................................68Rigaku/MSC ......................................................................................................................................................................................68Daylight Chemical Information Systems .....................................................................................................................................69Maybridge .........................................................................................................................................................................................69

Product................................................................................................................................................................................. 69Janssen Research Foundation .......................................................................................................................................................69Aventis ................................................................................................................................................................................................69Mitsubishi Pharma ..........................................................................................................................................................................69AstraZeneca ......................................................................................................................................................................................70Institute of Cancer Research and Cancer Research Technology .............................................................................................70The Wellcome Trust, the Institute of Cancer Research, Cancer Research Technology and GlaxoSmithKline ................71Schering AG ......................................................................................................................................................................................71Fujisawa Pharmaceutical ...............................................................................................................................................................72Boehringer Ingelheim ....................................................................................................................................................................72Novartis ..............................................................................................................................................................................................72Pfizer ...................................................................................................................................................................................................72University of Newcastle upon Tyne/Cancer Research Technology .........................................................................................73GlaxoSmithKline ...............................................................................................................................................................................73Janssen Pharmaceutica ..................................................................................................................................................................73


Platform,.Pipeline,.Products.............................................................................................................................................. 73Corporate.Environment.......................................................................................................................................................74

bIOVEx.......................................................................................................................................................... 75Key Personnel .......................................................................................................................................................................... 75Company Overview ................................................................................................................................................................ 75Milestones ................................................................................................................................................................................ 76R&D Pipeline ............................................................................................................................................................................77

BioVex R&D Pipeline, August 2008 ......................................................................................................................................................................................................77Oncology.............................................................................................................................................................................. 77

OncoVEX GM-CSF .............................................................................................................................................................................77Virology................................................................................................................................................................................ 78

Table of Contents

©Espicom Business Intelligence September 2008viii


ImmunoVEXHSV2 .............................................................................................................................................................................78Patents ...................................................................................................................................................................................... 78Agreements ............................................................................................................................................................................. 78

Wyeth.Pharmaceuticals...................................................................................................................................................... 78merck.&.Co........................................................................................................................................................................... 78National.Institutes.of.Health.............................................................................................................................................. 78



bIOxELL........................................................................................................................................................ 81Key Personnel .......................................................................................................................................................................... 81Company Overview ................................................................................................................................................................ 81Milestones ................................................................................................................................................................................82R&D Pipeline ............................................................................................................................................................................82

BioXell R&D Pipeline, August 2008 ......................................................................................................................................................................................................82urology................................................................................................................................................................................. 83

BXL628/Elocalcitol ...........................................................................................................................................................................83Pain.Relief............................................................................................................................................................................ 83

MNAC13 ..............................................................................................................................................................................................83musculoskeletal................................................................................................................................................................... 83

BXL093 ................................................................................................................................................................................................83Inflammation....................................................................................................................................................................... 84

TREM-1................................................................................................................................................................................................84TREM Programme ............................................................................................................................................................................84BXL746 ................................................................................................................................................................................................84

Technologies............................................................................................................................................................................84The.VD3.platform................................................................................................................................................................ 84mNAC13.Platform................................................................................................................................................................ 84The.TREm.platform.............................................................................................................................................................. 85

Agreements .............................................................................................................................................................................85Roche.................................................................................................................................................................................... 85Lay.Line.Genomics............................................................................................................................................................... 85merck.&.Co........................................................................................................................................................................... 85Galapagos/Proskelia........................................................................................................................................................... 86Zambon................................................................................................................................................................................ 86



bRuIN.PHARmACEuTICALs......................................................................................................................... 89Key Personnel ..........................................................................................................................................................................89Company Overview ................................................................................................................................................................89R&D Pipeline ............................................................................................................................................................................90

Cardiology............................................................................................................................................................................ 90D-4F ....................................................................................................................................................................................................90

Key Financial Data ..................................................................................................................................................................90Appraisal & Evaluation ...........................................................................................................................................................90

Platform,.Pipeline,.Products.............................................................................................................................................. 90Corporate.Environment.......................................................................................................................................................91

CELLECTIs..................................................................................................................................................... 93

Table of Contents

©Espicom Business Intelligence ixSeptember 2008


Key Personnel .......................................................................................................................................................................... 93Company Overview ................................................................................................................................................................ 93Milestones ................................................................................................................................................................................94R&D Pipeline ............................................................................................................................................................................94

Oncology.............................................................................................................................................................................. 95Meganucleases targeting p53 .......................................................................................................................................................95Meganucleases targeting XPC .......................................................................................................................................................95

Immunology........................................................................................................................................................................ 95Meganuclease targeting IL2RG .....................................................................................................................................................95Meganuclease targeting RAG1 ......................................................................................................................................................96

Patents ......................................................................................................................................................................................96Agreements ............................................................................................................................................................................. 97

Artemis.Pharmaceuticals.................................................................................................................................................... 97Deltagen............................................................................................................................................................................... 97Nucleis.................................................................................................................................................................................. 97fermentas............................................................................................................................................................................ 97Diversa.................................................................................................................................................................................. 97Regeneron.Pharmaceuticals.............................................................................................................................................. 97murinus................................................................................................................................................................................ 98Ascenion............................................................................................................................................................................... 98Lexicon.Genetics.................................................................................................................................................................. 99Celliance............................................................................................................................................................................... 99xenogen.biosciences........................................................................................................................................................... 99Ozgene................................................................................................................................................................................. 99biogen.Idec.......................................................................................................................................................................... 99AstraZeneca......................................................................................................................................................................... 99shire.Pharmaceuticals...................................................................................................................................................... 100Celonic................................................................................................................................................................................ 100Genentech.......................................................................................................................................................................... 100GlaxosmithKline................................................................................................................................................................ 100Laboratoires.servier.......................................................................................................................................................... 100TransGenic.......................................................................................................................................................................... 100

Key Financial Data ................................................................................................................................................................ 101Appraisal & Evaluation ......................................................................................................................................................... 101

Platform,.Pipeline,.Products.............................................................................................................................................101Corporate.Environment.....................................................................................................................................................101

COmbINATORx........................................................................................................................................... 103Key Personnel ........................................................................................................................................................................103Company Overview ..............................................................................................................................................................103Milestones ..............................................................................................................................................................................104R&D Pipeline ..........................................................................................................................................................................105

CombinatoRx R&D Pipeline, August 2008 .........................................................................................................................................................................................105Immuno-inflammatory..................................................................................................................................................... 106

CRx-102 .............................................................................................................................................................................................106CRx-139 .............................................................................................................................................................................................106

Pain..................................................................................................................................................................................... 106CRx-170 .............................................................................................................................................................................................106

Dermatology...................................................................................................................................................................... 106CRx-191 .............................................................................................................................................................................................106CRx-197 .............................................................................................................................................................................................106

metabolism........................................................................................................................................................................ 106

Table of Contents

©Espicom Business Intelligence September 2008x


CRx-401 ............................................................................................................................................................................................106Other.Research.Programmes........................................................................................................................................... 107

Technologies..........................................................................................................................................................................108Drug.Discovery.Platforms................................................................................................................................................. 108

Patents ....................................................................................................................................................................................108Agreements ...........................................................................................................................................................................109

sosei.................................................................................................................................................................................... 109Accelerate.brain.Cancer.Cure.(AbC2)................................................................................................................................ 109The.National.Institutes.of.Allergy.and.Infectious.Diseases........................................................................................... 109HenKan.Pharmaceutical.Company.................................................................................................................................. 109Angiotech.Pharmaceuticals..............................................................................................................................................110bio*One.Capital..................................................................................................................................................................110fovea.Pharmaceuticals.sA.................................................................................................................................................111Cystic.fibrosis.foundation.Therapeutics.........................................................................................................................111Cure.Huntington's.Disease.Initiative................................................................................................................................111Charley’s.fund/The.Nash.Avery.foundation....................................................................................................................112spinal.muscular.Atrophy.foundation.(smA.foundation)...............................................................................................112sAIC.-.National.Institute.of.Neurological.Disorders.and.stroke.....................................................................................112



DELTANOID.PHARmACEuTICALs...............................................................................................................115Key Personnel ........................................................................................................................................................................ 115Company Overview .............................................................................................................................................................. 115Milestones .............................................................................................................................................................................. 115R&D Pipeline .......................................................................................................................................................................... 116

Osteoporosis.......................................................................................................................................................................1162MD ...................................................................................................................................................................................................116

Agreements ........................................................................................................................................................................... 116Abbott.................................................................................................................................................................................116



DIATOs.........................................................................................................................................................119Key Personnel ........................................................................................................................................................................ 119Company Overview .............................................................................................................................................................. 119Milestones .............................................................................................................................................................................. 120R&D Pipeline .......................................................................................................................................................................... 121

Diatos R&D Pipeline, August 2008 ..................................................................................................................................................................................................... 121Oncology.............................................................................................................................................................................121

DaunoXome.....................................................................................................................................................................................121DTS-301 ............................................................................................................................................................................................122DTS-201 ............................................................................................................................................................................................122DTS-108 ............................................................................................................................................................................................123

Technologies.......................................................................................................................................................................... 123Drug.Development.Platforms...........................................................................................................................................123

Agreements ........................................................................................................................................................................... 124Gilead.sciences...................................................................................................................................................................124macromed...........................................................................................................................................................................124

Table of Contents

©Espicom Business Intelligence xiSeptember 2008


medarex...............................................................................................................................................................................124université.catholique.de.Louvain.....................................................................................................................................124Institut.Pasteur...................................................................................................................................................................124servier.................................................................................................................................................................................124OctoPlus.Technologies.......................................................................................................................................................125



EVOTEC....................................................................................................................................................... 127Key Personnel ........................................................................................................................................................................ 127Company Overview .............................................................................................................................................................. 127Milestones .............................................................................................................................................................................. 129R&D Pipeline ..........................................................................................................................................................................130

Evotec R&D Pipeline, August 2008 .....................................................................................................................................................................................................130Central.Nervous.system.....................................................................................................................................................131

EVT 201 .............................................................................................................................................................................................131EVT 101 ............................................................................................................................................................................................131EVT 103 .............................................................................................................................................................................................132EVT 302 ............................................................................................................................................................................................132VR1 Antagonist Programme ........................................................................................................................................................132P2X

3 and P2X

2/3 Antagonist Programme ...................................................................................................................................132

B1 antagonists ................................................................................................................................................................................133H3 antagonists ................................................................................................................................................................................133BACE inhibitors ...............................................................................................................................................................................133

Inflammatory.Disease........................................................................................................................................................133P2X

7 Antagonist Programme .......................................................................................................................................................133

MK2 inhibitors ................................................................................................................................................................................133Oncology.............................................................................................................................................................................133

Hsp90 inhibitors .............................................................................................................................................................................133Bcl-2, Bcl-xL and Mcl-1 inhibitors ................................................................................................................................................134

Technologies..........................................................................................................................................................................134High-throughput.screening.(HTs).Technology.............................................................................................................. 134EVOlution.platform........................................................................................................................................................... 134


boehringer.Ingelheim........................................................................................................................................................136Roche...................................................................................................................................................................................136Cure.Huntingdon’s.Disease.Initiative.(CHDI)...................................................................................................................137Ono.Pharmaceutical...........................................................................................................................................................137Intermune...........................................................................................................................................................................138Takeda.................................................................................................................................................................................138Interprotein.Corporation...................................................................................................................................................138Other.Research.Contracts..................................................................................................................................................138

Key Financial Data ................................................................................................................................................................ 139Appraisal & Evaluation .........................................................................................................................................................140

Platform,.Pipeline,.Products............................................................................................................................................ 140Corporate.Environment.................................................................................................................................................... 140

fIVEPRImE.THERAPEuTICs.........................................................................................................................141Key Personnel ........................................................................................................................................................................ 141Company Overview .............................................................................................................................................................. 141

Table of Contents

©Espicom Business Intelligence September 2008xii


Milestones .............................................................................................................................................................................. 142R&D Pipeline .......................................................................................................................................................................... 142

FivePrime Therapeutics R&D Pipeline, August 2008 ..........................................................................................................................................................................142Oncology.............................................................................................................................................................................143

FP-1039 .............................................................................................................................................................................................143FPT040 .............................................................................................................................................................................................143FPA005 ..............................................................................................................................................................................................143FPT069 ..............................................................................................................................................................................................143

metabolism.........................................................................................................................................................................143FPT038 ..............................................................................................................................................................................................143

Cardiology...........................................................................................................................................................................143FPT033/FPT057 ...............................................................................................................................................................................143

Gastrointestinal..................................................................................................................................................................143FPT042/FPT046 ...............................................................................................................................................................................143

Immunology...................................................................................................................................................................... 144FPT025 ..............................................................................................................................................................................................144

Technologies..........................................................................................................................................................................144Drug.Discovery.Platforms................................................................................................................................................. 144

Agreements ...........................................................................................................................................................................145Gene.Logic...........................................................................................................................................................................145biosite..................................................................................................................................................................................145boehringer.Ingelheim........................................................................................................................................................145Centocor/Johnson.&.Johnson............................................................................................................................................145Pfizer....................................................................................................................................................................................145

Key Financial Data ................................................................................................................................................................146Appraisal & Evaluation .........................................................................................................................................................146


GENmAb.A/s............................................................................................................................................... 147Key Personnel ........................................................................................................................................................................ 147Company Overview .............................................................................................................................................................. 147Milestones ..............................................................................................................................................................................148R&D Pipeline ..........................................................................................................................................................................150

Genmab R&D Pipeline, August 2008 .................................................................................................................................................................................................150Oncology.............................................................................................................................................................................151

HuMax-CD4 (zanolimumab) ........................................................................................................................................................151HuMax-CD20 (ofatumumab) ........................................................................................................................................................151HuMax-EGFr (zalutumumab) .......................................................................................................................................................152R1507 ................................................................................................................................................................................................153HuMax-IL8 .......................................................................................................................................................................................153HuMax-CD38 ...................................................................................................................................................................................153HuMax-CD32b .................................................................................................................................................................................153

Autoimmune/Anti-inflammatory.....................................................................................................................................153HuMax-CD20 (ofatumumab) ........................................................................................................................................................153AMG 714 ...........................................................................................................................................................................................154HuMax-IL8 .......................................................................................................................................................................................154HuMax-TAC ......................................................................................................................................................................................154

Neurology...........................................................................................................................................................................155HuMax-CD20 (ofatumumab) ........................................................................................................................................................155

Dermatology.......................................................................................................................................................................155HuMax-IL8 .......................................................................................................................................................................................155

Table of Contents

©Espicom Business Intelligence xiiiSeptember 2008


HuMax-TAC ......................................................................................................................................................................................155Respiratory..........................................................................................................................................................................155

Roche 4 .............................................................................................................................................................................................155Virology...............................................................................................................................................................................155

HuMax-HepC ...................................................................................................................................................................................155Transplant.Rejection..........................................................................................................................................................156

HuMax-TAC ......................................................................................................................................................................................156undisclosed.Indications.....................................................................................................................................................156

Roche 2 ............................................................................................................................................................................................156Roche 3 .............................................................................................................................................................................................156

Technologies..........................................................................................................................................................................156Antibody.Discovery.Engine...............................................................................................................................................156

Antibody Centre of Excellence .....................................................................................................................................................156UniBody............................................................................................................................................................................................157

Patents .................................................................................................................................................................................... 157Agreements ........................................................................................................................................................................... 157

Amgen.................................................................................................................................................................................157ACE.biosciences..................................................................................................................................................................157bionomics........................................................................................................................................................................... 158Cytokine.Pharmasciences................................................................................................................................................ 158Ganymed.Pharmaceuticals............................................................................................................................................... 158GlaxosmithKline................................................................................................................................................................ 158medarex..............................................................................................................................................................................159merck.serono......................................................................................................................................................................159Roche...................................................................................................................................................................................159


Platform,.Pipeline,.Products............................................................................................................................................ 160Corporate.Environment.....................................................................................................................................................161

IDENIx.PHARmACEuTICALs...................................................................................................................... 163Key Personnel ........................................................................................................................................................................163Company Overview ..............................................................................................................................................................163Milestones ..............................................................................................................................................................................164Marketed Products ...............................................................................................................................................................164R&D Pipeline ..........................................................................................................................................................................164

Idenix Pharmaceuticals R&D Pipeline, August 2008 .........................................................................................................................................................................165Virology.............................................................................................................................................................................. 165

IDX184 ..............................................................................................................................................................................................165IDX899 ..............................................................................................................................................................................................165IDX375 ..............................................................................................................................................................................................165IDX136/IDX316 Macrocyclic Protease Inhibitors ......................................................................................................................166

Discontinued Products ........................................................................................................................................................166Valopicitabine/NM283 ..................................................................................................................................................................166

Patents ....................................................................................................................................................................................166Agreements ........................................................................................................................................................................... 167

metabasis.Therapeutics.....................................................................................................................................................167Novartis.Pharma.................................................................................................................................................................167



Table of Contents

©Espicom Business Intelligence September 2008xiv


IKARIA......................................................................................................................................................... 171Key Personnel ........................................................................................................................................................................ 171Company Overview .............................................................................................................................................................. 171Milestones .............................................................................................................................................................................. 172Marketed Products ............................................................................................................................................................... 172R&D Pipeline .......................................................................................................................................................................... 173

Ikaria R&D Pipeline, August 2008 ......................................................................................................................................................................................................173Cardiology...........................................................................................................................................................................173

INOMax.............................................................................................................................................................................................173IK-1001 ..............................................................................................................................................................................................174

Immunology.......................................................................................................................................................................174Covox ................................................................................................................................................................................................174

Other.Research.Programmes............................................................................................................................................174Key Financial Data ................................................................................................................................................................ 174Appraisal & Evaluation ......................................................................................................................................................... 175


INfINITy.PHARmACEuTICALs................................................................................................................... 177Key Personnel ........................................................................................................................................................................ 177Company Overview .............................................................................................................................................................. 177Milestones .............................................................................................................................................................................. 178R&D Pipeline .......................................................................................................................................................................... 179

Infinity Pharmaceuticals R&D Pipeline, August 2008........................................................................................................................................................................179Oncology.............................................................................................................................................................................179

Retaspimycin ...................................................................................................................................................................................179IPI-493 ..............................................................................................................................................................................................180IPI-926 ...............................................................................................................................................................................................180Bcl-2 Protein Inhibitors..................................................................................................................................................................180

Technologies.......................................................................................................................................................................... 181Diversity.Oriented.synthesis.Technologies.....................................................................................................................181


medImmune/AstraZeneca.................................................................................................................................................181Novartis.............................................................................................................................................................................. 182Amgen................................................................................................................................................................................ 182Johnson.&.Johnson........................................................................................................................................................... 182



INTERCyTEx............................................................................................................................................... 185Key Personnel ........................................................................................................................................................................185Company Overview ..............................................................................................................................................................185Milestones ..............................................................................................................................................................................186R&D Pipeline ..........................................................................................................................................................................186

Intercytex R&D Pipeline, August 2008 ...............................................................................................................................................................................................186Dermatology...................................................................................................................................................................... 186

ICX-PRO (cyzact) .............................................................................................................................................................................186VAVELTA ...........................................................................................................................................................................................187ICX-TRC .............................................................................................................................................................................................187ICX-SKN.............................................................................................................................................................................................188

Table of Contents

©Espicom Business Intelligence xvSeptember 2008


Technologies..........................................................................................................................................................................188Agreements ...........................................................................................................................................................................188

baxter.Healthcare............................................................................................................................................................. 188The.Automation.Partnership........................................................................................................................................... 189Armed.forces.Institute.of.Regenerative.medicine......................................................................................................... 189



IRONWOOD.PHARmACEuTICALs.............................................................................................................. 191Key Personnel ........................................................................................................................................................................ 191Company Overview .............................................................................................................................................................. 191Milestones .............................................................................................................................................................................. 192R&D Pipeline .......................................................................................................................................................................... 192

Ironwood Pharmaceuticals R&D Pipeline, August 2008 ...................................................................................................................................................................192Gastrointestinal..................................................................................................................................................................193

MD-1100/linaclotide ......................................................................................................................................................................193Cardiology...........................................................................................................................................................................193

MD-0727 ..........................................................................................................................................................................................193Agreements ........................................................................................................................................................................... 193

forest.Laboratories............................................................................................................................................................193Key Financial Data ................................................................................................................................................................194Appraisal & Evaluation .........................................................................................................................................................194


KAI.PHARmACEuTICALs............................................................................................................................ 195Key Personnel ........................................................................................................................................................................195Company Overview ..............................................................................................................................................................195Milestones ..............................................................................................................................................................................196R&D Pipeline ..........................................................................................................................................................................196

KAI Pharmaceuticals, August 2008 ....................................................................................................................................................................................................196Cardiology...........................................................................................................................................................................197

KAI-9803 ..........................................................................................................................................................................................197KAI-1455 ...........................................................................................................................................................................................197

Pain.management..............................................................................................................................................................197KAI-1678 ...........................................................................................................................................................................................197Gamma PKC ....................................................................................................................................................................................197

Ophthalmology..................................................................................................................................................................197Beta PKC ..........................................................................................................................................................................................197

Inflammatory.Disease....................................................................................................................................................... 198Theta PKC Inhibition ......................................................................................................................................................................198

Agreements ...........................................................................................................................................................................198sankyo................................................................................................................................................................................ 198bristol-myers.squibb........................................................................................................................................................ 198



KALyPsys................................................................................................................................................... 201Key Personnel ........................................................................................................................................................................201Company Overview ..............................................................................................................................................................201

Table of Contents

©Espicom Business Intelligence September 2008xvi


Milestones ..............................................................................................................................................................................202R&D Pipeline ..........................................................................................................................................................................202

Kalypsys R&D Pipeline, August 2008 .................................................................................................................................................................................................202metabolism........................................................................................................................................................................ 203

KD3010 ............................................................................................................................................................................................ 203KD3020 ............................................................................................................................................................................................ 203

Pain..................................................................................................................................................................................... 203KD7040 ............................................................................................................................................................................................ 203

Oncology............................................................................................................................................................................ 203KD5170 ............................................................................................................................................................................................ 203

Technologies..........................................................................................................................................................................203Agreements ...........................................................................................................................................................................204

merck.&.Co......................................................................................................................................................................... 204CV.Therapeutics................................................................................................................................................................. 204Los.Alamos.National.Laboratory..................................................................................................................................... 204National.Institutes.of.Health............................................................................................................................................ 204NovImmune....................................................................................................................................................................... 205Eidogen-sertanty.............................................................................................................................................................. 205Alcon................................................................................................................................................................................... 205



KEREOs....................................................................................................................................................... 207Key Personnel ........................................................................................................................................................................207Company Overview ..............................................................................................................................................................207Milestones ..............................................................................................................................................................................208R&D Pipeline ..........................................................................................................................................................................208

Kereos R&D Pipeline, August 2008.....................................................................................................................................................................................................208Oncology............................................................................................................................................................................ 208

KI-0001 ............................................................................................................................................................................................ 208KI-100X ............................................................................................................................................................................................ 208KM-4419 .......................................................................................................................................................................................... 209

Cardiology.......................................................................................................................................................................... 209KI-0002 ........................................................................................................................................................................................... 209KI-1004 ............................................................................................................................................................................................ 209

Technologies..........................................................................................................................................................................209Ligand-Targeted.Emulsion.Technologies........................................................................................................................ 209

Agreements ........................................................................................................................................................................... 210Philips..................................................................................................................................................................................210Lantheus.medical.Imaging.(bristol-myers.squibb.medical.Imaging)...........................................................................210Dow.Chemical.....................................................................................................................................................................210Washington.university......................................................................................................................................................211



mICROmET...................................................................................................................................................213Key Personnel ........................................................................................................................................................................ 213Company Overview .............................................................................................................................................................. 213Milestones .............................................................................................................................................................................. 214

Table of Contents

©Espicom Business Intelligence xviiSeptember 2008


R&D Pipeline .......................................................................................................................................................................... 215Micromet R&D Pipeline, August 2008 ...............................................................................................................................................................................................216BiTE Antibody Only Pipeline ...............................................................................................................................................................................................................217

Oncology.............................................................................................................................................................................217MT103/MEDI-538 ............................................................................................................................................................................217Adecatumumab (MT201) ..............................................................................................................................................................218MT293 (D93/TRC093) .................................................................................................................................................................... 220MT110 ...............................................................................................................................................................................................221MT111 ................................................................................................................................................................................................221MT228 (MORAb-028) .....................................................................................................................................................................221bscEphA2xCD3 .............................................................................................................................................................................. 222muS110 ............................................................................................................................................................................................ 222Antibodies targeting CD33 and MCSP ...................................................................................................................................... 222

Inflammatory/Autoimmune.Diseases............................................................................................................................. 222MT203 .............................................................................................................................................................................................. 222MT204 .............................................................................................................................................................................................. 223

Technologies..........................................................................................................................................................................223biTE.(bispecific.T-Cell.Engagers).Technology.................................................................................................................. 223single.Chain.Antibodies.................................................................................................................................................... 223


Enzon.Pharmaceuticals..................................................................................................................................................... 224Abbott,.Alligator.bioscience.Ab,.Haptogen.and.A.N.Other........................................................................................... 224Cambridge.Antibody.Technology.(CAT).......................................................................................................................... 224EsbATech.AG...................................................................................................................................................................... 225medImmune...................................................................................................................................................................... 225serono................................................................................................................................................................................ 226EvoGenix.Pty...................................................................................................................................................................... 226Novuspharma.spA............................................................................................................................................................. 226TRACON.Pharmaceuticals................................................................................................................................................. 227morphotek......................................................................................................................................................................... 227Nycomed............................................................................................................................................................................ 227university.of.southern.California.................................................................................................................................... 227Applied.molecular.Evolution/Eli.Lilly.............................................................................................................................. 228Arizeke.Pharmaceuticals.................................................................................................................................................. 228Antigenics.......................................................................................................................................................................... 228Viventia.barbados............................................................................................................................................................. 228



mOLECuLAR.INsIGHT.PHARmACEuTICALs.............................................................................................. 231Key Personnel ........................................................................................................................................................................231Company Overview ..............................................................................................................................................................231Milestones ..............................................................................................................................................................................232R&D Pipeline ..........................................................................................................................................................................233

Molecular Insight R&D Pipeline, August 2008 ...................................................................................................................................................................................233Oncology............................................................................................................................................................................ 233

Azedra ..............................................................................................................................................................................................233Onalta .............................................................................................................................................................................................. 234Solazed ............................................................................................................................................................................................ 234

Table of Contents

©Espicom Business Intelligence September 2008xviii


Trofex ............................................................................................................................................................................................... 234Cardiology.......................................................................................................................................................................... 235

Zemiva ............................................................................................................................................................................................ 235MIP-190............................................................................................................................................................................................ 235

Neurology.......................................................................................................................................................................... 235MIP-170D ......................................................................................................................................................................................... 235

Technologies..........................................................................................................................................................................236ultratrace.Technology...................................................................................................................................................... 236sAAC.Technology............................................................................................................................................................... 236sAACQ.Technology............................................................................................................................................................ 236Nanotrace.Discovery......................................................................................................................................................... 236


bayer.schering.Pharma..................................................................................................................................................... 237Novartis.Pharma................................................................................................................................................................ 237



NEuROmED.PHARmACEuTICALs.............................................................................................................. 241Key Personnel ........................................................................................................................................................................ 241Company Overview .............................................................................................................................................................. 241Milestones ..............................................................................................................................................................................242R&D Pipeline ..........................................................................................................................................................................243

Neuromed Pharmaceuticals Pipeline, August 2008 ..........................................................................................................................................................................243Pain..................................................................................................................................................................................... 243

NMED-160 ........................................................................................................................................................................................243NMED-1077 .....................................................................................................................................................................................243Others .............................................................................................................................................................................................. 244

Other.Indications............................................................................................................................................................... 244Agreements ...........................................................................................................................................................................244

merck.&.Co......................................................................................................................................................................... 244Key Financial Data ................................................................................................................................................................245Appraisal & Evaluation .........................................................................................................................................................245


NOVExEL.................................................................................................................................................... 247Key Personnel ........................................................................................................................................................................247Company Overview ..............................................................................................................................................................247Milestones ..............................................................................................................................................................................248R&D Pipeline ..........................................................................................................................................................................248

Novexel R&D Pipeline, August 2008 ..................................................................................................................................................................................................248Antibacterial...................................................................................................................................................................... 248

NXL103 ............................................................................................................................................................................................. 248NXL101 ..............................................................................................................................................................................................249NXL104 ..............................................................................................................................................................................................249NXL105 .............................................................................................................................................................................................249

Antifungal.......................................................................................................................................................................... 249NXL201 .............................................................................................................................................................................................249

Agreements ...........................................................................................................................................................................250Indevus.Pharmaceuticals.................................................................................................................................................. 250

Table of Contents

©Espicom Business Intelligence xixSeptember 2008


forest.Laboratories........................................................................................................................................................... 250Key Financial Data ................................................................................................................................................................250Appraisal & Evaluation .........................................................................................................................................................250


NPs.PHARmACEuTICALs........................................................................................................................... 253Key Personnel ........................................................................................................................................................................253Company Overview ..............................................................................................................................................................253Milestones ..............................................................................................................................................................................255R&D Pipeline ..........................................................................................................................................................................256

NPS Pharmaceuticals R&D Pipeline, August 2008 .............................................................................................................................................................................256Gastrointestinal................................................................................................................................................................. 257

GATTEX ............................................................................................................................................................................................ 257musculoskeletal................................................................................................................................................................. 257

PREOS/Preotact ............................................................................................................................................................................. 257calcilytics ......................................................................................................................................................................................... 258

Central.Nervous.system.................................................................................................................................................... 258NPSP156 .......................................................................................................................................................................................... 258

metabolism........................................................................................................................................................................ 258NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) ............................................................................................ 258

Renal................................................................................................................................................................................... 258Cinacalcet HCl ................................................................................................................................................................................ 258


Amgen................................................................................................................................................................................ 259Kirin.Pharma...................................................................................................................................................................... 260Nycomed............................................................................................................................................................................ 260DRI.Capital...........................................................................................................................................................................261GlaxosmithKline.................................................................................................................................................................261Janssen............................................................................................................................................................................... 262AstraZeneca....................................................................................................................................................................... 262Ortho-mcNeil.Pharmaceuticals........................................................................................................................................ 262



OPTImER.PHARmACEuTICALs.................................................................................................................. 265Key Personnel ........................................................................................................................................................................265Company Overview ..............................................................................................................................................................265Milestones ..............................................................................................................................................................................266R&D Pipeline ..........................................................................................................................................................................267

Optimer Pharmaceuticals R&D Pipeline, August 2008 ......................................................................................................................................................................267Antibacterial...................................................................................................................................................................... 267

OPT-80 ..............................................................................................................................................................................................267Prulifloxacin (OPT-99) ................................................................................................................................................................... 268OPT-1068/CEM-101 ........................................................................................................................................................................ 269

musculoskeletal................................................................................................................................................................. 269OPT-88 ............................................................................................................................................................................................. 269

Oncology............................................................................................................................................................................ 269OPT-822/OPT-821 .......................................................................................................................................................................... 269

Technologies..........................................................................................................................................................................270

Table of Contents

©Espicom Business Intelligence September 2008xx


Drug.Discovery.Platform.................................................................................................................................................. 270Patents ....................................................................................................................................................................................270Agreements ...........................................................................................................................................................................271

C&O.Pharmaceutical.Technology.(Holdings).................................................................................................................. 271Par.Pharmaceutical............................................................................................................................................................ 271biocon................................................................................................................................................................................. 271Nippon.shinyaku............................................................................................................................................................... 271sloan-Kettering.Institute.for.Cancer.Research............................................................................................................... 272Cempra.Pharmaceuticals.................................................................................................................................................. 272The.scripps.Research.Institute......................................................................................................................................... 273Inc.Research....................................................................................................................................................................... 273National.Institute.of.Allergy.and.Infectious.Diseases.................................................................................................... 273



PALATIN.TECHNOLOGIEs........................................................................................................................... 275Key Personnel ........................................................................................................................................................................275Company Overview ..............................................................................................................................................................275Milestones ..............................................................................................................................................................................276R&D Pipeline ..........................................................................................................................................................................277

Palatin Technologies R&D Pipeline, August 2008 ..............................................................................................................................................................................277Cardiology.......................................................................................................................................................................... 277

Bremelanotide ................................................................................................................................................................................277PL-6983 .............................................................................................................................................................................................278Natriuretic Receptor Compounds/PL-3994 ...............................................................................................................................278

metabolism........................................................................................................................................................................ 278Melanocortin-based Therapeutics .............................................................................................................................................278

Imaging/Diagnosis............................................................................................................................................................ 278NeutroSpec ......................................................................................................................................................................................278

Technologies..........................................................................................................................................................................279Drug.Development.Platforms.......................................................................................................................................... 279

MIDAS Drug Development Platform ..........................................................................................................................................279NeutroSpec ......................................................................................................................................................................................279


AstraZeneca....................................................................................................................................................................... 280mallinckrodt...................................................................................................................................................................... 280



PHARmAmAR............................................................................................................................................. 283Key Personnel ........................................................................................................................................................................283Company Overview ..............................................................................................................................................................283Milestones ..............................................................................................................................................................................284R&D Pipeline ..........................................................................................................................................................................284

PharmaMar R&D Pipeline, August 2008 ...........................................................................................................................................................................................284Oncology............................................................................................................................................................................ 285

Yondelis (trabectedin) .................................................................................................................................................................. 285Aplidin (plitidepsin) ...................................................................................................................................................................... 286

Table of Contents

©Espicom Business Intelligence xxiSeptember 2008


PM02734 ......................................................................................................................................................................................... 287Kahalalide F ................................................................................................................................................................................... 287Zalypsis............................................................................................................................................................................................ 287Thiocoraline ................................................................................................................................................................................... 288Variolins .......................................................................................................................................................................................... 288Lamellarins ..................................................................................................................................................................................... 288

Dermatology...................................................................................................................................................................... 288Kahalalide F ................................................................................................................................................................................... 288

Agreements ...........................................................................................................................................................................288Johnson.&.Johnson........................................................................................................................................................... 288Innovex............................................................................................................................................................................... 288swedish.Orphan.International......................................................................................................................................... 288Genesis.Pharma................................................................................................................................................................. 288Cenit-Nanopharma.Consortium...................................................................................................................................... 289



PRANA.bIOTECHNOLOGy.......................................................................................................................... 291Key Personnel ........................................................................................................................................................................291Company Overview ..............................................................................................................................................................291Milestones ..............................................................................................................................................................................293R&D Pipeline ..........................................................................................................................................................................294

Prana Biotechnology R&D Pipeline, August 2008 .............................................................................................................................................................................294Central.Nervous.system.................................................................................................................................................... 294

PBT2 ................................................................................................................................................................................................. 294Drug Candidate ............................................................................................................................................................................. 295Amyloid-inhibiting compounds ................................................................................................................................................. 295

Immunotherapy................................................................................................................................................................ 296MAbs against Abeta ...................................................................................................................................................................... 296

Oncology............................................................................................................................................................................ 296PBT1/others .................................................................................................................................................................................... 296

Ophthalmology................................................................................................................................................................. 296MPAC Compounds ........................................................................................................................................................................ 296

Discontinued Products ........................................................................................................................................................297Central.Nervous.system.................................................................................................................................................... 297

PBT1 (Clioquinol) ........................................................................................................................................................................... 297Patents ....................................................................................................................................................................................297Agreements ...........................................................................................................................................................................298

schering.AG........................................................................................................................................................................ 298Australian.Industry.Research.and.Development.board................................................................................................ 298



REPLIDyNE................................................................................................................................................. 301Key Personnel ........................................................................................................................................................................301Company Overview ..............................................................................................................................................................301Milestones ..............................................................................................................................................................................302R&D Pipeline ..........................................................................................................................................................................303

Replidyne R&D Pipeline, August 2008 ...............................................................................................................................................................................................303

Table of Contents

©Espicom Business Intelligence September 2008xxii


Antibacterial...................................................................................................................................................................... 303Faropenem medoxomil ............................................................................................................................................................... 303REP3123/REP8839 ......................................................................................................................................................................... 305DNA Replication Inhibitors Programme ................................................................................................................................... 306


forest.Laboratories........................................................................................................................................................... 307Asubio.Pharma.................................................................................................................................................................. 307



s*bIO............................................................................................................................................................311Key Personnel ........................................................................................................................................................................ 311Company Overview .............................................................................................................................................................. 311Milestones .............................................................................................................................................................................. 312R&D Pipeline .......................................................................................................................................................................... 312

Clinical.Trials.......................................................................................................................................................................312HDAC .................................................................................................................................................................................................312Kinase Programme ........................................................................................................................................................................312S*BIO R&D Pipeline, 2008 .................................................................................................................................................................................................................. 313

Technology ............................................................................................................................................................................ 313Agreements ........................................................................................................................................................................... 313

A*sTAR.................................................................................................................................................................................313Genome.Institute.of.singapore.........................................................................................................................................314Karolinska.Institutet..........................................................................................................................................................314National.university.Hospital,.singapore.........................................................................................................................314



sOsEI............................................................................................................................................................315Key Personnel ........................................................................................................................................................................ 315Company Overview .............................................................................................................................................................. 315Milestones .............................................................................................................................................................................. 317R&D Pipeline .......................................................................................................................................................................... 317

Sosei R&D Pipeline, August 2008 ....................................................................................................................................................................................................... 317Respiratory.system............................................................................................................................................................318

NVA237 .............................................................................................................................................................................................318QVA149 .............................................................................................................................................................................................318

Oncology.............................................................................................................................................................................319AD923 ...............................................................................................................................................................................................319

Central.Nervous.system.....................................................................................................................................................319AD337 ...............................................................................................................................................................................................319SD118 ................................................................................................................................................................................................319

Inflammation.and.Immunology...................................................................................................................................... 320SD726 ................................................................................................................................................................................................320SD208 ................................................................................................................................................................................................320

Women’s.Healthcare......................................................................................................................................................... 320SOH-075 ...........................................................................................................................................................................................320

Agreements ...........................................................................................................................................................................320

Table of Contents

©Espicom Business Intelligence xxiiiSeptember 2008


mundipharma.................................................................................................................................................................... 320sandoz.................................................................................................................................................................................321CombinatoRx......................................................................................................................................................................321



sPEEDEL.PHARmACEuTICALs................................................................................................................... 323Key Personnel ........................................................................................................................................................................323Company Overview ..............................................................................................................................................................323Milestones ..............................................................................................................................................................................325R&D Pipeline ..........................................................................................................................................................................327

Speedel R&D Pipeline, August 2008 ..................................................................................................................................................................................................327Cardiology.......................................................................................................................................................................... 328

SPP100 (aliskiren,Tekturna, Rasilez) ...........................................................................................................................................328SPP200 (pegmusirudin) ................................................................................................................................................................329SPP301 (avosentan) ........................................................................................................................................................................329SPP600 .............................................................................................................................................................................................330SPP635 ..............................................................................................................................................................................................330SPP676 ..............................................................................................................................................................................................330SPP800 Series ..................................................................................................................................................................................330SPP1100 Series ................................................................................................................................................................................331SPP2000 Series ...............................................................................................................................................................................331

Agreements ........................................................................................................................................................................... 331Locus.Pharmaceuticals......................................................................................................................................................331Novartis...............................................................................................................................................................................331Roche.................................................................................................................................................................................. 332Abbott.Laboratories.......................................................................................................................................................... 332



syNTA.PHARmACEuTICALs....................................................................................................................... 335Key Personnel ........................................................................................................................................................................335Company Overview ..............................................................................................................................................................335Milestones ..............................................................................................................................................................................337R&D Pipeline ..........................................................................................................................................................................338

Synta Pharmaceuticals R&D Pipeline, August 2008 ..........................................................................................................................................................................338Oncology............................................................................................................................................................................ 338

STA-4783 (elesclomol) ...................................................................................................................................................................338STA-9090 ..........................................................................................................................................................................................339STA-9584 ..........................................................................................................................................................................................339STA-5312 ...........................................................................................................................................................................................339

Inflammatory.Disease....................................................................................................................................................... 340STA-5326 (apilimod mesylate) .................................................................................................................................................... 340Crohn’s Disease .............................................................................................................................................................................. 340Rheumatoid Arthritis ................................................................................................................................................................... 340Common Variable Immunodeficiency ...................................................................................................................................... 340Psoriasis........................................................................................................................................................................................... 340CRAC ion channel inhibitor ......................................................................................................................................................... 340

Technologies..........................................................................................................................................................................341

Table of Contents

©Espicom Business Intelligence September 2008xxiv


Chemical.Library................................................................................................................................................................ 341screening.Assays............................................................................................................................................................... 341In.vivo.Testing.Capabilities............................................................................................................................................... 341Chemistry.Capabilities...................................................................................................................................................... 341Target.Elucidation............................................................................................................................................................. 341


GlaxosmithKline................................................................................................................................................................ 342Key Financial Data ................................................................................................................................................................343Appraisal & Evaluation .........................................................................................................................................................343


syNTAxIN................................................................................................................................................... 345Key Personnel ........................................................................................................................................................................345Company Overview ..............................................................................................................................................................345Milestones ..............................................................................................................................................................................346R&D Pipeline ..........................................................................................................................................................................346

Syntaxin R&D Pipeline, August 2008 .................................................................................................................................................................................................346Pain..................................................................................................................................................................................... 347

Un-named Product ........................................................................................................................................................................347Respiratory......................................................................................................................................................................... 347

SYN187 .............................................................................................................................................................................................347Other................................................................................................................................................................................... 347

Endocrinology Products ...............................................................................................................................................................347Obesity Products ........................................................................................................................................................................... 348Nerve Disorder Products ............................................................................................................................................................. 348

Agreements ...........................................................................................................................................................................348Allergan.............................................................................................................................................................................. 348



TAKARA.bIO................................................................................................................................................ 349Key Personnel ........................................................................................................................................................................349Company Overview ..............................................................................................................................................................349Milestones ..............................................................................................................................................................................350R&D Pipeline ..........................................................................................................................................................................350

Oncology............................................................................................................................................................................ 350HSV-TK gene therapies ................................................................................................................................................................ 350T-cell receptor (TCR) gene therapy .............................................................................................................................................351Cancer Immunotherapy ...............................................................................................................................................................351Cancer Immunity Reconstruction Therapy ...............................................................................................................................351

Virology.............................................................................................................................................................................. 352VRX496 ............................................................................................................................................................................................352MazF Gene Therapy .......................................................................................................................................................................352

Technologies..........................................................................................................................................................................352Research.Reagents.and.scientific.Instruments.............................................................................................................. 352Contract.Research.services.............................................................................................................................................. 353

Agreements ...........................................................................................................................................................................353InVivoscribe.Technologies............................................................................................................................................... 353memorial.sloan-Kettering.Cancer.Center....................................................................................................................... 353

Table of Contents

©Espicom Business Intelligence xxvSeptember 2008


Peter.macCallum.Cancer.Centre....................................................................................................................................... 354Green.Cross.Corporation.................................................................................................................................................. 354New.England.biolabs........................................................................................................................................................ 354Transgenomic..................................................................................................................................................................... 354Kemp.biotechnologies...................................................................................................................................................... 354Tianjin.medical.university................................................................................................................................................ 354



THERAVANCE............................................................................................................................................. 357Key Personnel ........................................................................................................................................................................357Company Overview ..............................................................................................................................................................357Milestones ..............................................................................................................................................................................358R&D Pipeline ..........................................................................................................................................................................359

Theravance R&D Pipeline, August 2008 ............................................................................................................................................................................................359Antibacterial...................................................................................................................................................................... 359

Telavancin ........................................................................................................................................................................................359TD-1792 ........................................................................................................................................................................................... 360

Respiratory..........................................................................................................................................................................361GW642444 .......................................................................................................................................................................................361GW685698 .......................................................................................................................................................................................361GSK159797 .......................................................................................................................................................................................361GSK1160724 .................................................................................................................................................................................... 362GSK656398...................................................................................................................................................................................... 362GSK961081 ...................................................................................................................................................................................... 362

Gastrointestinal................................................................................................................................................................. 362TD-5108 ........................................................................................................................................................................................... 363TD-2749 ........................................................................................................................................................................................... 363TD-6301 ........................................................................................................................................................................................... 363


Astellas............................................................................................................................................................................... 364GlaxosmithKline................................................................................................................................................................ 364AstraZeneca....................................................................................................................................................................... 366



TRANZymE.PHARmA................................................................................................................................. 369Key Personnel ........................................................................................................................................................................369Company Overview ..............................................................................................................................................................369Milestones ..............................................................................................................................................................................370R&D Pipeline ..........................................................................................................................................................................370

Tranzyme Pharma R&D Pipeline, August 2008 .................................................................................................................................................................................370Gastrointestinal................................................................................................................................................................. 371

TZP-101 .............................................................................................................................................................................................371TZP-102 .............................................................................................................................................................................................372TZP-201 .............................................................................................................................................................................................372TZP-301 ............................................................................................................................................................................................372

Technologies..........................................................................................................................................................................372

Table of Contents

©Espicom Business Intelligence September 2008xxvi


Drug.Discovery.Platform.................................................................................................................................................. 372Macrocyclic Template Chemistry (MATCH) ................................................................................................................................372


Neokimia/Trimeris............................................................................................................................................................ 373Key Financial Data ................................................................................................................................................................373Appraisal & Evaluation .........................................................................................................................................................373

Platform,.Pipeline,.Products............................................................................................................................................ 373Corporate.Environment.....................................................................................................................................................374

TRImERIs.................................................................................................................................................... 375Key Personnel ........................................................................................................................................................................375Company Overview ..............................................................................................................................................................375Milestones ..............................................................................................................................................................................377Marketed Products ...............................................................................................................................................................378

Virology.............................................................................................................................................................................. 378FUZEON ............................................................................................................................................................................................378

R&D Pipeline ..........................................................................................................................................................................379Virology.............................................................................................................................................................................. 379

FUZEON ............................................................................................................................................................................................379TRI-1144 ........................................................................................................................................................................................... 380


Roche.................................................................................................................................................................................. 381Array.biopharma............................................................................................................................................................... 382Neokimia/Tranzyme......................................................................................................................................................... 382Chembridge.Research.Laboratories................................................................................................................................ 383New.york.blood.Center..................................................................................................................................................... 383



TRubION.PHARmACEuTICALs.................................................................................................................. 387Key Personnel ........................................................................................................................................................................387Company Overview ..............................................................................................................................................................387Milestones ..............................................................................................................................................................................388R&D Pipeline ..........................................................................................................................................................................389

Trubion Pharmaceuticals R&D Pipeline, August 2008 .......................................................................................................................................................................389Autoimmune/Inflammatory.Diseases............................................................................................................................. 389

TRU-015 ........................................................................................................................................................................................... 389SBI-087 ............................................................................................................................................................................................ 390

Oncology............................................................................................................................................................................ 390TRU-015 ........................................................................................................................................................................................... 390TRU-016 ............................................................................................................................................................................................391

Technologies..........................................................................................................................................................................391Product.Engine.................................................................................................................................................................. 391


Wyeth................................................................................................................................................................................. 392Key Financial Data ................................................................................................................................................................393Appraisal & Evaluation .........................................................................................................................................................393

Platform,.Pipeline,.Products............................................................................................................................................ 393

Table of Contents

©Espicom Business Intelligence xxviiSeptember 2008


Corporate.Environment.................................................................................................................................................... 393VIROPHARmA............................................................................................................................................. 395

Key Personnel ........................................................................................................................................................................395Company Overview ..............................................................................................................................................................395Milestones ..............................................................................................................................................................................397Marketed Products ...............................................................................................................................................................398

Antibacterial...................................................................................................................................................................... 398Vancocin .......................................................................................................................................................................................... 398

R&D Pipeline ..........................................................................................................................................................................398ViroPharma R&D Pipeline, August 2008 ...........................................................................................................................................................................................398

Virology.............................................................................................................................................................................. 399Maribavir (CAMVIA) ...................................................................................................................................................................... 399CDI Programme ............................................................................................................................................................................. 400

Anti-inflammatory............................................................................................................................................................ 400C1 inhibitor (human) ..................................................................................................................................................................... 400

Discontinued Products ........................................................................................................................................................400Virology.............................................................................................................................................................................. 400

Picovir (Pleconaril)......................................................................................................................................................................... 400Hepatitis C Candidates ................................................................................................................................................................. 400HCV371 ............................................................................................................................................................................................ 401HCV-086 .......................................................................................................................................................................................... 401HCV-796........................................................................................................................................................................................... 401


GlaxosmithKline................................................................................................................................................................ 402sanofi-synthélabo/sanofi-aventis................................................................................................................................... 402schering-Plough................................................................................................................................................................ 404Eli.Lilly................................................................................................................................................................................. 404Wyeth................................................................................................................................................................................. 404



WILEx.......................................................................................................................................................... 409Key Personnel ........................................................................................................................................................................409Company Overview ..............................................................................................................................................................409Milestones .............................................................................................................................................................................. 411R&D Pipeline .......................................................................................................................................................................... 413

WILEX R&D Pipeline, August 2008 ..................................................................................................................................................................................................... 413Oncology.............................................................................................................................................................................414

WX-G250 and WX-G250RIT (RENCAREX) ...................................................................................................................................414WX-UK1 ............................................................................................................................................................................................414K931 ..................................................................................................................................................................................................415WX-671 (MESUPRON) ....................................................................................................................................................................415CA9-SCAN (REDECTANE) ...............................................................................................................................................................416WX-77X Series .................................................................................................................................................................................416


Centocor..............................................................................................................................................................................417bayer....................................................................................................................................................................................417Vu.university.medical.Center.Amsterdam......................................................................................................................417

Table of Contents

©Espicom Business Intelligence September 2008xxviii


fox.Chase.Cancer.Center....................................................................................................................................................417Esteve..................................................................................................................................................................................418IbA.molecular......................................................................................................................................................................418


Platform,.Pipeline,.Products.............................................................................................................................................419Corporate.Environment.................................................................................................................................................... 420

xENCOR...................................................................................................................................................... 421Key Personnel ........................................................................................................................................................................421Company Overview ..............................................................................................................................................................421Milestones ..............................................................................................................................................................................422R&D Pipeline ..........................................................................................................................................................................422

Xencor R&D Pipeline, August 2008 ....................................................................................................................................................................................................422Inflammatory.Disease....................................................................................................................................................... 422

XPro1595 ..........................................................................................................................................................................................423Oncology............................................................................................................................................................................ 423

XmAb2513 .......................................................................................................................................................................................423Oncology/Inflammatory.Disease..................................................................................................................................... 423

XmAb5574 .......................................................................................................................................................................................423XmAb5871 .......................................................................................................................................................................................424XmAb5485 ......................................................................................................................................................................................424

Technologies..........................................................................................................................................................................424Protein.Design.Automation............................................................................................................................................. 424xPro.................................................................................................................................................................................... 425

XmAb technology ..........................................................................................................................................................................425ImmunoPDA ....................................................................................................................................................................................425


Caltech................................................................................................................................................................................ 426Torrey.mesa.Research.Institute........................................................................................................................................ 426Protein.Design.Labs.......................................................................................................................................................... 426Eli.Lilly................................................................................................................................................................................. 427Genentech.......................................................................................................................................................................... 427Chugai.Pharmaceutical..................................................................................................................................................... 427Centocor............................................................................................................................................................................. 427medImmune...................................................................................................................................................................... 427Roche.................................................................................................................................................................................. 428boehringer.Ingelheim....................................................................................................................................................... 428Human.Genome.sciences................................................................................................................................................. 428



EsPICOm.ANALysIs.................................................................................................................................... 433Winners & Losers ..................................................................................................................................................................433Biopharmaceutical Company R&D Pipelines ..................................................................................................................434

Phase.III.Drug.Candidates................................................................................................................................................. 435Phase III Drug Candidates ..................................................................................................................................................................................................................435

Methodology .........................................................................................................................................................................436Company.Ratings.............................................................................................................................................................. 436

Section Name

who s developing what in global biopharmaceuticals...september 2008 ©espicom business intelligence...

Documents